Whitehawk Therapeutics (WHWK) Cash from Investing Activities (2016 - 2026)

Whitehawk Therapeutics (WHWK) has 11 years of Cash from Investing Activities data on file, last reported at $19.4 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 83.18% year-over-year to $19.4 million in Q1 2026; TTM through Mar 2026 was -$84.2 million, a 164.68% decrease from a year earlier, with the FY2025 full-year figure at $11.9 million, down 52.82% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $19.4 million, up from $16.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for WHWK reached as high as $115.5 million in Q1 2025 and fell as low as -$91.6 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged $402529.4 across 5 years, with a median of $5.1 million in 2024.
• Across the five-year window, Cash from Investing Activities tumbled 183332.61% in 2022 and surged 71095.65% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$84.4 million in 2022, then surged by 104.32% to $3.6 million in 2023, then jumped by 259.91% to $13.1 million in 2024, then rose by 28.27% to $16.8 million in 2025, then gained by 15.34% to $19.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $19.4 million in Q1 2026, $16.8 million in Q4 2025, and -$91.6 million in Q3 2025.